Skip to main content
. 2024 Jun 3;16(7):1495–1514. doi: 10.1038/s44321-024-00084-4

Figure EV4. In vivo testing of anti-GD2-IRDye800CW and anti-L1CAM-IRDye800CW in NB xenografts.

Figure EV4

(AD) Line graph depicting the TBR (A, B) and MFI (C, D) of anti-GD2-IRDye800CW (A, C) and anti-L1CAM-IRDye800CW (B, D) per dose on 7 consecutive days. Mean TBR or MFI ± SD as imaged with the IVIS Spectrum system, n = 3 to 4 mice per dose group. (E, F) Bargraphs of the biodistribution of anti-GD2-IRDye800CW at day 5 (E) and anti-L1CAM-IRDye800CW at day 6 (F) in subcutaneous NB tumor-bearing mice receiving a 1 nmol dose. Mean MFI of organs and tissues normalized to the tumor + SD of n = 3 mice per probe. (G, H) Representative images of the biodistribution of anti-GD2-IRDye800CW at day 5 (G) and anti-L1CAM-IRDye800CW at day 6 (H) in subcutaneous NB tumor-bearing mice receiving a 1 nmol dose.